RecruitingPhase 3NCT06615050
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Incyte Medical MonitorIncyte Corporation
- Intervention
- Tacrolimus (Tac)(drug)
- Enrollment
- 572 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (28)
- Stanford Cancer Center, Palo Alto, California, United States
- University of California San Francisco, San Francisco, California, United States
- University of Miami, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Kansas Hospital Authority, Kansas City, Kansas, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Mount Sinai Hospital, New York, New York, United States
- Memorial Sloan Kettering, New York, New York, United States
- University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
- +13 more locations on ClinicalTrials.gov
Collaborators
Blood and Marrow Transplant Clinical Trials Network · National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI) · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06615050 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE4NCT06824103Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University